MAPP BIOPHARMACEUTICAL, INC.

CANCELLING FUNDS UNDER REQUISITION OS240615 UNDER CLIN 0001 EXPIRING 10/01/2025

PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES - TRANSFER GFP

ANTIBODY & ANTIGEN SUPPLY

SUPPLEMENTAL AGREEMENT TO FUND CLIN 0001 AND UPDATE STATEMENT OF WORK.

BIOPHARMACEUTICAL CELL CREATION

THE PURPOSE OF THIS IS TO UPDATE ARTICLES B.2, B.3, F.2(A) AND ARTICLE G.1, G.5, EXTEND POP FOR CLIN 0001, CLIN 0004, CLIN 0005, AND PROVIDE SUPPLEMENTAL FUNDING UNDER CLIN0001.

DEVELOPMENT OF MEDICAL COUNTERMEASURES THROUGH PLANNED CLINICAL TRIALS AND OUTBREAK PREPAREDNESS

MACHUPO VIRUS CELL SORTING FOR MONOCLONAL ANTIBODY DISCOVERY

PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES

THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.

THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FULLY FUND OPTION 4/CLIN0005, NO-COST EXTENSION OF CLIN0001 THROUGH 6/30/2024, AND REVISE TRAVEL COSTS

THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE AND FULLY FUND OPTION 3 CLIN0004, UPDATE SOW, PROVIDE ADDITIONAL FUNDING FOR CLIN0001, ESTABLISH OPTION 4 CLIN0005, AND EXTEND THE PERIOD OF PERFORMANCE (POP) FOR CLIN0001

THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.

LABORATORY TESTING. SECTION 711 (NDAA) 2019 THE (USAMRAA), U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USAMRDC) TRANSFERRED TO THE DEFENSE HEALTH AGENCY (DHA) FROM THE U.S. ARMY EFFECTIVE 01 OCTOBER 2022

PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES

ADVANCE MBP134, A COCKTAIL OF TWO HUMAN MONOCLONAL ANTIBODIES (MBP047 AND MBP087), AS A POTENTIAL MEDICAL COUNTERMEASURE TO TREAT ACTIVE INFECTIONS OF SUDAN VIRUS

MAPP BIOPHARMACEUTICAL - SUPPLEMENTAL FUNDING FOR CLIN 0001 INDIRECT RATES.

THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.

PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES

SUPPORT THE INITIATION, MAINTENANCE, AND EXECUTION OF A ZMAPP EAP IN THE US AND AFRICA, INCLUDING CLINICAL, QUALITY, REGULATORY, AND OPERATIONAL SUPPORT AS WELL AS THE EARLY CLINICAL STUDIES (PHASE 1) REQUIRED TO ENABLE FIELD USE OF MBP091 AND MBP134

DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE

SUPPLEMENTAL FUNDING FOR CLIN 0002

DEVELOPMENT OF A PAN-BOTULINUM NEUROTOXIN MEDICAL COUNTERMEASURE

THE PURPOSE OF THIS MODIFICATION IS TO ADD ADDITIONAL FUNDING FOR CLIN 0004.

INCORPORATE REVISED STATEMENT OF WORK AND ADD FUNDING FOR CLIN 0005